The Association Between HIV-1 Tat and Vif Amino Acid Sequence Variation, Inflammation and Trp-Kyn Metabolism: an Exploratory Investigation

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Sep 9

PMID 39251983

Authors

Monray E Williams

Levanco K Asia

Zander Lindeque

Esme Jansen Van Vuren

Affiliations

Soon will be listed here.

Abstract

Background: HIV-1 has well-established mechanisms to disrupt essential pathways in people with HIV, such as inflammation and metabolism. Moreover, diversity of the amino acid sequences in fundamental HIV-1 proteins including Tat and Vif, have been linked to dysregulating these pathways, and subsequently influencing clinical outcomes in people with HIV. However, the relationship between Tat and Vif amino acid sequence variation and specific immune markers and metabolites of the tryptophan-kynurenine (Trp-Kyn) pathway remains unclear. Therefore, this study aimed to investigate the relationship between Tat/Vif amino acid sequence diversity and Trp-Kyn metabolites (quinolinic acid (QUIN), Trp, kynurenic acid (KA), Kyn and Trp/Kyn ratio), as well as specific immune markers (sCD163, suPAR, IL-6, NGAL and hsCRP) in n = 67 South African cART-naïve people with HIV.

Methods: Sanger sequencing was used to determine blood-derived Tat/Vif amino acid sequence diversity. To measure Trp-Kyn metabolites, a LC-MS/MS metabolomics platform was employed using a targeted approach. To measure immune markers, Enzyme-linked immunosorbent assays and the Particle-enhanced turbidimetric assay was used.

Results: After adjusting for covariates, sCD163 (p = 0.042) and KA (p = 0.031) were higher in participants with Tat signatures N24 and R57, respectively, and amino acid variation at position 24 (adj R = 0.048, β = -0.416, p = 0.042) and 57 (adj R = 0.166, β = 0.535, p = 0.031) of Tat were associated with sCD163 and KA, respectively.

Conclusions: These preliminary findings suggest that amino acid variation in Tat may have an influence on underlying pathogenic HIV-1 mechanisms and therefore, this line of work merits further investigation.

References

Schmitt K, Hill M, Ruiz A, Culley N, Pinson D, Wong S . Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology. 2008; 383(2):362-72. PMC: 4104693. DOI: 10.1016/j.virol.2008.10.013. View

Williams M . HIV-1 Vif protein sequence variations in South African people living with HIV and their influence on Vif-APOBEC3G interaction. Eur J Clin Microbiol Infect Dis. 2023; 43(2):325-338. PMC: 10821834. DOI: 10.1007/s10096-023-04728-0. View

Paul R, Joska J, Woods C, Seedat S, Engelbrecht S, Hoare J . Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease. J Neurovirol. 2014; 20(6):627-35. PMC: 4268069. DOI: 10.1007/s13365-014-0293-z. View

Castley A, Williams L, James I, Guelfi G, Berry C, Nolan D . Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors. PLoS One. 2016; 11(6):e0158169. PMC: 4927121. DOI: 10.1371/journal.pone.0158169. View

Yang G, Xiong X . Viral infectivity factor: a novel therapeutic strategy to block HIV-1 replication. Mini Rev Med Chem. 2013; 13(7):1047-55. DOI: 10.2174/1389557511313070008. View

Asia L, Jansen Van Vuren E, Lindeque Z, Williams M . A pilot investigation of the association between HIV-1 Vpr amino acid sequence diversity and the tryptophan-kynurenine pathway as a potential mechanism for neurocognitive impairment. Virol J. 2024; 21(1):47. PMC: 10893664. DOI: 10.1186/s12985-024-02313-1. View

Lv T, Cao W, Li T . HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies. J Immunol Res. 2021; 2021:7316456. PMC: 8494587. DOI: 10.1155/2021/7316456. View

Knudsen T, Ertner G, Petersen J, Moller H, Moestrup S, Eugen-Olsen J . Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. J Infect Dis. 2016; 214(8):1198-204. DOI: 10.1093/infdis/jiw263. View

Ranga U, Shankarappa R, Siddappa N, Ramakrishna L, Nagendran R, Mahalingam M . Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol. 2004; 78(5):2586-90. PMC: 369202. DOI: 10.1128/jvi.78.5.2586-2590.2004. View

10.

Asia L, Jansen Van Vuren E, Williams M . The influence of viral protein R amino acid substitutions on clinical outcomes in people living with HIV: A systematic review. Eur J Clin Invest. 2022; 53(5):e13943. DOI: 10.1111/eci.13943. View

11.

Iwabu Y, Kinomoto M, Tatsumi M, Fujita H, Shimura M, Tanaka Y . Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J Biol Chem. 2010; 285(46):35350-8. PMC: 2975159. DOI: 10.1074/jbc.M110.173286. View

12.

Williams M, Ipser J, Stein D, Joska J, Naude P . The Association of Immune Markers with Cognitive Performance in South African HIV-Positive Patients. J Neuroimmune Pharmacol. 2019; 14(4):679-687. DOI: 10.1007/s11481-019-09870-1. View

13.

Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H . Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets. 2012; 12(1):81-6. DOI: 10.2174/187152612798994939. View

14.

Generoso M, Alvarez P, Kravietz A, Mwamzuka M, Marshed F, Ahmed A . High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection. AIDS. 2019; 34(1):33-38. DOI: 10.1097/QAD.0000000000002378. View

15.

Rao V, Neogi U, Talboom J, Padilla L, Rahman M, Fritz-French C . Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology. 2013; 10:61. PMC: 3686704. DOI: 10.1186/1742-4690-10-61. View

16.

Badawy A, Guillemin G . The Plasma [Kynurenine]/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal. Int J Tryptophan Res. 2019; 12:1178646919868978. PMC: 6710706. DOI: 10.1177/1178646919868978. View

17.

Ruhanya V, Jacobs G, Paul R, Joska J, Seedat S, Nyandoro G . HIV-1 subtype C Tat exon-1 amino acid residue 24K is a signature for neurocognitive impairment. J Neurovirol. 2022; 28(3):392-403. DOI: 10.1007/s13365-022-01073-4. View

18.

Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden T . NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci. 2008; 28(47):12190-8. PMC: 6671692. DOI: 10.1523/JNEUROSCI.3019-08.2008. View

19.

Teo K, Chow C, Vaz M, Rangarajan S, Yusuf S . The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J. 2009; 158(1):1-7.e1. DOI: 10.1016/j.ahj.2009.04.019. View

20.

Yousaf M, Zia S, Babar M, Ashfaq U . The epidemic of HIV/AIDS in developing countries; the current scenario in Pakistan. Virol J. 2011; 8:401. PMC: 3173394. DOI: 10.1186/1743-422X-8-401. View